Knee Pain Chronic
Conditions
Brief summary
The prevalence of Chronic Post-Surgical Pain (CPSP) after knee replacement, defined as pain greater than or equal to 4/10 on the visual analogue scale after the third postoperative month, is recognised as high, with an average of 20% (extremes of 7 to 45%). These CPSP, when present, cause poor long-term joint functional prognosis and impaired quality of life for patients. Many predictive, pre-, per- and post-operative factors of these CPSP have been identified in recent years. The most common postoperative risk factor found in the literature is the intensity of early pain. The treatment protocols for this early post-surgical pain are currently and mainly multimodal in nature, combining systemic analgesics (paracetamol, NSAIDs, morphine, gabapentins) and local anaesthetics, administered either in the form of peripheral nerve blocks (continuous or single injection) or in the form of tissue infiltration (TI) performed by the surgeon during the operation. Very few of these techniques have been evaluated for their ability to reduce the incidence of CPSP. Drugs with antihyperalgesic properties such as ketamine or nefopam have been shown to be of no interest, except to reduce the proportion of pain of a neuropathic nature. Only the continuous femoral block has shown, to date, an interest in IT to reduce the incidence of these CPSP. The main objective of this study is to show that a multimodal analgesia protocol based on continuous locoregional analgesia by femoral triangle catheterization could reduce the incidence of chronic post surgical pain compared to a protocol based on tissue infiltration.
Interventions
DRUGRopivacaine
Locoregional analgesia by femoral triangle catheterization
Sponsors
Centre Hospitalier Departemental Vendee
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Adult patient; * Placement of unilateral tricompartmental knee prosthesis for gonarthrosis; * ASA score between I and III ; * Nonseptic scheduled surgery; * Knee replacement scheduled on one of the first 3 days of the week (Monday to Wednesday included) in order to benefit from a homogeneous postoperative physical therapy; * Able to understand the protocol; * Having agreed to participate in the study and having given express oral consent; * Affiliated with a social security system; * Possibility of being followed as part of the protocol.
Exclusion criteria
* Age \>= 86 years old; * BMI \> 35 ; * Revision of knee replacement; * Symptomatic contralateral osteoarthritis; * Anterior of surgery on the operated knee (excluding arthroscopy and meniscectomy); * Vascular surgery on the femoral vessels on the operated side; * Concept of diffuse polyalgia syndrome (fibromyalgia); * Documented neuropathy of the lower limb; * Localized infection at the catheter puncture site (femoral triangle); * Known allergy to Ropivacaine; * Renal insufficiency (Clearance - CKD-EPI formula - creatinine \<30 ml/min) and/or severe hepatic insufficiency (prothrombin blood level \<50%) ; * Inflammatory rheumatic disease (rheumatoid arthritis, ankylosing spondylitis...) ; * Patients on immunosuppressive or systemically administered corticosteroid therapy; * Daily use of level II or III analgesics for more than one month pre-operatively; * Known intolerance to tier III analgesics; * Allergy or contraindications to standard treatments administered per and postoperatively (paracetamol, NSAIDs); * Patient undergoing knee surgery in the year prior to inclusion and participating in the study; * Patients who do not cooperate or do not understand French, difficulties in understanding and evaluating the pain score, preoperative cognitive dysfunction making the interview unreliable; * Patient under guardianship, curators, deprivation of liberty; * Patient already engaged in another interventional clinical study (category 1); * Pregnant or breastfeeding women, or women in a position to procreate who refuse an effective means of contraception; * Refusal to participate; * Inability to understand the protocol and its requirements, and/or to give express oral consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Walking Pain Assessment Scale | Three months from the intervention | Self-assessment scale to quantify the patient's pain on a virtual scale from 0 (no pain) to 10 (maximum pain imaginable). Measure is positive when score is \>= 4 |
Countries
France
Contacts
STUDY_DIRECTORJérôme GUILLEY
CHD Vendée
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 71 years |
| BMI | 27.4 kg/m² |
| Douleur Neuropathique en 4 questions | 2 units on a scale |
| Race and Ethnicity Not Collected | 0 Participants |
| Rest Pain Assessment Scale | 2 units on a scale |
| Sex: Female, Male Female | 77 Participants |
| Sex: Female, Male Male | 67 Participants |
| Walking Pain Assessment Scale | 5 units on a scale |
| WOMAC Score | 47 units on a scale |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 143 | 0 / 144 |
| other Total, other adverse events | 0 / 143 | 0 / 144 |
| serious Total, serious adverse events | 0 / 143 | 0 / 144 |
Outcome results
None listed